Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Environment and reproductive health in China: challenges and opportunities.

Environmental health perspectives·2012

Same author

Posttransplant mortality risk assessment for adult-to-adult right-lobe living donor liver recipients with benign end-stage liver disease.

Scandinavian journal of gastroenterology·2012

Same author

Sodium nitrite protects against kidney injury induced by brain death and improves post-transplant function.

Kidney international·2012

Same author

OIC-A006-loaded true bone ceramic heals rabbit critical-sized segmental radial defect.

Die Pharmazie·2012

Same author

Liquid chromatography-mass spectrometric multiple reaction monitoring-based strategies for expanding targeted profiling towards quantitative metabolomics.

Current drug metabolism·2012

Same author

Structural and functional characterization of mature forms of metalloprotease E495 from Arctic sea-ice bacterium Pseudoalteromonas sp. SM495.

PloS one·2012

Search research articles

Related Experiment Video

Updated: May 6, 2026

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

Prognostic and immunotherapeutic potential of disulfidptosis-associated signature in pancreatic cancer.

Ran Cui¹, Gaoming Wang², Renhao Hu¹

¹Department of Hepatopancreatobiliary Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.

Frontiers in Immunology

|April 10, 2025

Summary

This summary is machine-generated.

Disulfidptosis, a programmed cell death, plays a key role in pancreatic ductal adenocarcinoma. This study developed an 8-gene signature to predict prognosis and immune checkpoint blockade sensitivity in PDAC patients.

Keywords:

disulfidptosis immunotherapy pancreatic adenocarcinoma prognostic signature tumor microenvironment

More Related Videos

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

Related Experiment Videos

Last Updated: May 6, 2026

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Immunophenotyping of Orthotopic Homograft Syngeneic of Murine Primary KPC Pancreatic Ductal Adenocarcinoma by Flow Cytometry

Published on: October 9, 2018

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

Area of Science:

Oncology
Cell Biology
Bioinformatics

Background:

Disulfidptosis is a newly identified programmed cell death mechanism.
The role of disulfidptosis in pancreatic ductal adenocarcinoma (PDAC) is not well understood.

Purpose of the Study:

To investigate the significance of disulfidptosis in PDAC.
To develop a prognostic signature for PDAC based on disulfidptosis-related genes.

Main Methods:

Integrated multi-omics data (bulk RNA-seq, microarray, single-cell, spatial transcriptomics) and biospecimens.
Screened and validated disulfidptosis-related genes using bioinformatics.
Constructed and validated an 8-gene prognostic signature (DPS) using LASSO-Cox regression and external PDAC cohorts.

Main Results:

An 8-gene disulfidptosis-related prognostic signature (DPS) was established and validated.
High DPS scores correlated with poorer prognosis and reduced sensitivity to immune checkpoint blockade.
Elevated DPS was linked to tumor hallmarks, myCAF-tumor cell interactions, and immune cell exclusion.

Conclusions:

A novel, highly effective disulfidptosis-related signature aids in PDAC patient risk stratification.
The signature can predict sensitivity to immune checkpoint blockade therapy.
MyCAF-tumor cell crosstalk, mediated by signaling networks, contributes to PDAC malignancy.